Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary05/10/2017
PHILADELPHIA, PA -- (Marketwired) -- 05/10/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Company to initiate a Phase 2 clinical trial in 2H 2017, targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial Responder subset is approximately 10% of the US
Toggle Summary05/03/2017
PHILADELPHIA, PA -- (Marketwired) -- 05/03/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today it will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 8:30 a.m. EDT to report financial results for the first quarter and discuss recent business
Toggle Summary04/27/2017
PHILADELPHIA, PA -- (Marketwired) -- 04/27/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Thursday, May 4, 2017 at 1:10 p.m.
Toggle Summary04/20/2017
PHILADELPHIA, PA -- (Marketwired) -- 04/20/17 -- -- Novel genetic mutations predictive of response to AEVI-001 found in approximately 10% of pediatric ADHD patients -- -- New results clarify a path forward for the continued development of AEVI-001 in ADHD patients and potential future development
Toggle Summary04/12/2017
PHILADELPHIA, PA -- (Marketwired) -- 04/12/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6 th World Congress on ADHD (Attention Deficit Hyperactivity
Toggle Summary03/30/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/30/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Brian D. Piper , Chief Financial Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m.
Toggle Summary03/20/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/20/17 -- Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose (400 mg BID) Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo) Clear signal of efficacy and benefit to
Toggle Summary03/15/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/15/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference on Wednesday, March 22, 2017 at 3:20 p.m.
Toggle Summary03/09/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line data from SAGA Phase 2/3 trial of AEVI-001 in adolescents with mGluR+ ADHD to be announced by end of Q1 Robust pipeline with data from several AEVI-001 signal finding studies expected in 2017 Aevi
Toggle Summary02/27/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/27/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2016 at